Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

nds that inhibit the kinase FMS which have been demonstrated to have excellent potency and selectivity. Approximately 4,000 additional novel compounds have been amassed from Cytopia's own research and are being reviewed. YM's other discovery programs include the IntellimabÒ platform of uniquely optimized antibodies designed to selectively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Japan , April 16, 2015  Center ... University and Takeda Pharmaceutical Company Limited (Takeda) announced ... clinical applications of induced pluripotent stem cells in ... disorders and cancer immunotherapy. The "Takeda-CiRA Joint Program ... expedite multiple research projects for drug discovery and ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased to ... for the 2015 BIO International Convention. Hosted by the ... will take place June 15-18 at the Pennsylvania Convention ... contest, industry leaders will be voting for companies they ... community voting period began on April 14, 2015 and ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... a Tool to Make Soyfoods Even HealthierST. LOUIS, March ... healthcare professionals believe soy to be beneficial to the ... method to make food products such as soyfoods even ... Biotechnology Awareness & Attitude Survey - sponsored by ...
... cell line manufacturing, Selexis is now offering a ... drugs with added characterization servicesGENEVA, March 31 ... and services for the rapid development of high-performance ... offering focusing on the biosimilar market segment. ...
... March 31 Sigma-Aldrich (Nasdaq: ... quality services and oligonucleotides to Gene Oracle, an innovative ... agreement, Sigma-Aldrich will be the exclusive supplier of custom ... engage in co-marketing efforts to promote the GeneIOS system ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Selexis Launches Biosimilar Cell Line Development Program 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... study of more than 68,000 infants published in this ... Rotateq demonstrated that it can safely prevent 98 percent ... account for 2 million hospital visits and 500,000 pediatric ... largest pre-licensure vaccine clinical trials ever conducted worldwide, research ...
... against the Epstein-Barr virus, the virus that most often ... sclerosis 15 to 20 years later, according to a ... June 2006 print issue of Archives of Neurology, one ... that external factors may influence the risk for multiple ...
... called statins do not appear to reduce the incidence ... of previous studies in the January 4 issue of ... the risk of developing cancer, the authors provide as ... been studied in numerous large-scale, randomized, active- or placebo-controlled ...
Cached Biology News:New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3Epstein-Barr virus may be associated with multiple sclerosis 2Statins have neutral effect on risk of cancer 2
CQCS kit for etra KR 4i , (other units)....
... of VARIOMAG Magnetic Stirrers operate without any ... mechanical bearings, making VARIOMAG Magnetic Stirrers 100% ... inductive drive can be hermetically sealed, making ... This is why VARIOMAG Magnetic Stirrers are ...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
...
Biology Products: